このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

標準リスクの多発性骨髄腫と新たに診断された参加者を対象とした、ダラツムマブ、ボルテゾミブ、レナリドミドおよびデキサメタゾンによる導入後のCilta-cel、タルケタマブとダラツムマブの併用およびテクリスタマブとダラツムマブの併用の異なるシーケンスの研究 (aMMbition)

2026年11月2日 更新者:Janssen Research & Development, LLC

チルタカブタゲン オートロイセル (Cilta-cel)、タルケタマブ SC とダラツムマブ SC の併用 (Tal-D)、およびテクリスタマブ SC とダラツムマブ SC の併用 (Tec-D) のさまざまな配列の有効性と安全性を評価する第 2 相非盲検試験)新たに多発性骨髄腫と診断された標準リスクの参加者におけるダラツムマブ、ボルテゾミブ、レナリドミドおよびデキサメタゾン(DVRd)による導入後

The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.

調査の概要

研究の種類

介入

入学 (実際)

43

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope
      • San Francisco、California、アメリカ、94143
        • University of California San Francisco
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa Hospital and Clinics
    • New York
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28204
        • Levine Cancer Institute
      • Melbourne、オーストラリア、3004
        • The Alfred Hospital
      • Melbourne、オーストラリア、3000
        • Peter MacCallum Cancer Centre
      • Madrid、スペイン、28041
        • Hosp. Univ. 12 de Octubre
      • Salamanca、スペイン、37007
        • Hosp Clinico Univ de Salamanca
      • Santander、スペイン、39008
        • Hosp. Univ. Marques de Valdecilla
      • Heidelberg、ドイツ、69120
        • Universitaetsklinikum Heidelberg
      • Tübingen、ドイツ、72076
        • Universitaetsklinikum Tuebingen
      • Würzburg、ドイツ、97080
        • Universitatsklinikum Wurzburg
      • Salvador、ブラジル、41253-190
        • IDOR - Regional Bahia
      • São Paulo、ブラジル、01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo、ブラジル、05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
  • Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
  • Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
  • Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

Exclusion Criteria:

  • Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
  • Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
  • Stroke or seizure within 6 months of signing the informed consent form (ICF)
  • Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
  • Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
  • Seropositive for human immunodeficiency virus (HIV)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel

Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen.

Talquetamab will be administered subcutaneously.

他の名前:
  • JNJ-64407564

Cilta-cel infusion will be administered intravenously.

他の名前:
  • JNJ-68284528、シルタカブタゲン オートロイセル

Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.

他の名前:
  • JNJ-54767414

Bortezomib will be administered subcutaneously as a part of induction.

Lenalidomide will be administered orally as a part of induction.

Dexamethasone will be administered orally as a part of induction.

Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Fludarabine will be administered intravenously as a part of conditioning regimen.

実験的:Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation

Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval.

Talquetamab will be administered subcutaneously.

他の名前:
  • JNJ-64407564

Teclistamab will be administered subcutaneously.

他の名前:
  • JNJ-64007957

Cilta-cel infusion will be administered intravenously.

他の名前:
  • JNJ-68284528、シルタカブタゲン オートロイセル

Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.

他の名前:
  • JNJ-54767414

Bortezomib will be administered subcutaneously as a part of induction.

Lenalidomide will be administered orally as a part of induction.

Dexamethasone will be administered orally as a part of induction.

Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Fludarabine will be administered intravenously as a part of conditioning regimen.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of Response with Curative Potential
時間枠:Up to 5 years

Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments.

Up to 5 years
Progression Free Survival (PFS) Rate at 3-Year
時間枠:At 3-year

PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first.

At 3-year
PFS Rate at 5-Year
時間枠:At 5-year

PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first.

At 5-year

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate (ORR; Partial response [PR] or better)
時間枠:Up to 5 years

ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria.

Up to 5 years
CR or Better Rate
時間枠:Up to 5 years

Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria.

Up to 5 years
Very Good Partial Response (VGPR) or Better Rate
時間枠:Up to 5 years

Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria.

Up to 5 years
Duration of Response (DOR)
時間枠:Up to 5 years

DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first.

Up to 5 years
Time to First Response (TTR)
時間枠:Up to 5 years

Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response.

Up to 5 years
Duration of CR or Better Response
時間枠:Up to 5 years

Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first.

Up to 5 years
Time to First CR or Better Response
時間枠:Up to 5 years

Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria.

Up to 5 years
PFS on next line therapy (PFS2)
時間枠:Up to 5 years

PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first.

Up to 5 years
Overall Survival (OS)
時間枠:Up to 5 years

OS is measured from the date of randomization to the date of death due to any cause.

Up to 5 years
MRD-negative CR Rate
時間枠:Up to 5 years

MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria.

Up to 5 years
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
時間枠:Up to 5 years

An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events.

Up to 5 years
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
時間枠:Up to 5 years

Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

Up to 5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年8月20日

一次修了 (推定)

2030年9月2日

研究の完了 (推定)

2030年9月30日

試験登録日

最初に提出

2024年8月27日

QC基準を満たした最初の提出物

2024年8月27日

最初の投稿 (実際)

2024年8月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する